Ira Levy - Avivagen Interim Officer
| VIVXF Stock | USD 0.0001 0.00 0.00% |
Insider
Ira Levy is Interim Officer of Avivagen
| Phone | 613 702 2908 |
| Web | https://www.avivagen.com |
Avivagen Management Efficiency
The company has return on total asset (ROA) of (0.9546) % which means that it has lost $0.9546 on every $100 spent on assets. This is way below average. Avivagen's management efficiency ratios could be used to measure how well Avivagen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Daniel Neria | Genomma Lab Internacional | N/A | |
| Adalmario Couto | Hypera SA | N/A | |
| Marianne Velasco | Genomma Lab Internacional | N/A | |
| A MBA | Cumberland Pharmaceuticals | 66 | |
| Hlio Segouras | Hypera SA | N/A | |
| Justice Anderson | Procyon | 46 | |
| Juan Sparvieri | Genomma Lab Internacional | N/A | |
| Luiz Clavis | Hypera SA | N/A | |
| Efran Crdova | Genomma Lab Internacional | N/A | |
| L Porres | Genomma Lab Internacional | N/A | |
| Alejandro Patio | Genomma Lab Internacional | N/A | |
| Adam Mostafa | Cumberland Pharmaceuticals | 44 | |
| Juliana Salem | Hypera SA | N/A | |
| Jorge Valderrama | Genomma Lab Internacional | N/A | |
| Joao Aguilar | Hypera SA | N/A | |
| Mximo Juda | Genomma Lab Internacional | N/A | |
| Engineer Galland | Genomma Lab Internacional | N/A | |
| Mauricio Christovam | Hypera SA | N/A | |
| Cindy Patton | Cumberland Pharmaceuticals | 71 | |
Management Performance
| Return On Asset | -0.95 |
Avivagen Leadership Team
Elected by the shareholders, the Avivagen's board of directors comprises two types of representatives: Avivagen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avivagen. The board's role is to monitor Avivagen's management team and ensure that shareholders' interests are well served. Avivagen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avivagen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tracy BVSC, Director Mang | ||
| Drew Basek, Director Relations | ||
| James Nickerson, Pres Innovation | ||
| Graham Burton, Chief CoFounder | ||
| Ira Levy, Interim Officer | ||
| G Anthony, CEO Director |
Avivagen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Avivagen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.95 | |||
| Operating Margin | (12.34) % | |||
| Current Valuation | 9.01 M | |||
| Shares Outstanding | 77.19 M | |||
| Shares Owned By Insiders | 1.43 % | |||
| Price To Sales | 11.96 X | |||
| Revenue | 1.3 M | |||
| Gross Profit | 534.34 K | |||
| EBITDA | (4.68 M) | |||
| Net Income | (6.39 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in Avivagen Pink Sheet
Avivagen financial ratios help investors to determine whether Avivagen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Avivagen with respect to the benefits of owning Avivagen security.